Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma
MADISON, Wis. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today updates interim overall survival (OS) data from the company’s
View HTML
Toggle Summary Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference
MADISON, Wis. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that James Caruso , president and chief
View HTML
Toggle Summary Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma
MADISON, Wis. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the U.S.
View HTML
Toggle Summary Cellectar Biosciences Provides an Update on the FDA Import Alert
MADISON, Wis. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S.
View HTML
Toggle Summary FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
MADISON, Wis. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S.
View HTML
Toggle Summary Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
MADISON, Wis. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that James Caruso , president and chief
View HTML
Toggle Summary Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients
Positive Results from Cohort 5 of Phase 1b Trial Company Intends to Initiate a Sixth Cohort and Transition Ongoing Phase 2 Trial to a Fractionated Dose MADISON, Wis. , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the
View HTML
Toggle Summary Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma
MADISON, Wis. , Aug. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S.
View HTML
Toggle Summary Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update
MADISON, Wis. , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB)(“Cellectar or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported financial results for the
View HTML
Toggle Summary Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate
MADISON, Wis. and COURBEVOIE, France , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, and Orano Med (formerly AREVA Med) a subsidiary
View HTML